Health Status in the TORCH Study of COPD: Treatment Efficacy and Other Determinants of Change

DSpace/Manakin Repository

Health Status in the TORCH Study of COPD: Treatment Efficacy and Other Determinants of Change

Show simple item record Jones, Paul W Calverley, Peter MA Ferguson, Gary T Jenkins, Christine Yates, Julie C Spencer, Michael D Anderson, Julie A. Celli, Bartolome R Vestbo, Jorgen 2011-09-21T14:54:50Z 2011
dc.identifier.citation Jones, Paul W., Julie A. Anderson, Peter MA Calverley, Bartolome R. Celli, Gary T. Ferguson, Christine Jenkins, Julie C. Yates, Jorgen Vestbo, and Michael D. Spencer. 2011. Health status in the TORCH study of COPD: Treatment efficacy and other determinants of change. Respiratory Research 12(1): 71. en_US
dc.identifier.issn 1465-9921 en_US
dc.description.abstract Background: Little is known about factors that determine health status decline in clinical trials of COPD. Objectives: To examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone propionate (SFC) vs. salmeterol alone, fluticasone propionate alone or placebo. Methods: St George’s Respiratory Questionnaire (SGRQ) was administered at baseline then every 6 months. Measurements and Main Results: Data from 4951 patients in 28 countries were available. SFC produced significant improvements over placebo in all three SGRQ domains during the study: (Symptoms -3.6 [95% CI -4.8, -2.4], Activity -2.8 [95% CI -3.9, -1.6], Impacts -3.2 [95% CI -4.3, -2.1]) but the pattern of change over time differed between domains. SGRQ deteriorated faster in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III & IV relative to GOLD stage II (p < 0.001). There was no difference in the relationship between deterioration in SGRQ Total score and forced expiratory volume in one second (FEV1) decline (as % predicted) in men and women. Significantly faster deterioration in Total score relative to FEV1 % predicted was seen in older patients (≥ 65 years) and there was an age-related change in Total score that was independent of change in FEV1. The relationship between deterioration in \(FEV_1\) and SGRQ did not differ in different world regions, but patients in Asia-Pacific showed a large improvement in score that was unrelated to \(FEV_1\) change. Conclusions: In addition to treatment effects, health status changes in clinical trials may be influenced by demographic and disease-related factors. Deterioration in health status appears to be fastest in older persons and those with severe airflow limitation. en_US
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.relation.isversionof doi:10.1186/1465-9921-12-71 en_US
dc.relation.hasversion en_US
dash.license LAA
dc.subject COPD quality of life en_US
dc.subject health status en_US
dc.subject lung function en_US
dc.title Health Status in the TORCH Study of COPD: Treatment Efficacy and Other Determinants of Change en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Respiratory Research en_US Celli, Bartolome R 2011-09-21T14:54:50Z
dash.affiliation.other 100178 en_US

Files in this item

Files Size Format View
3117702.pdf 560.8Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record


Search DASH

Advanced Search